Compare Neurocrine Biosciences Inc (NBIX) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Prologis Inc — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while Prologis Inc trades at $128.94 (market cap $120.98B). The key difference: Prologis Inc is far larger — about 8.3× Neurocrine Biosciences Inc's market cap, and Prologis Inc pays a 3.36% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Prologis Inc for 102 Days on average.
| NBIX | PLD | |
|---|---|---|
Market Cap | $14.60B | $120.98B |
Volume | 1,075,694 | 3,604,776 |
Sector | Health | Real Estate |
52-Week High | $185.50 | $149.96 |
52-Week Low | $123.10 | $111.23 |
Typical Hold Time | 23 Days | 102 Days |
Enterprise Value | $14.61B | $155.72B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Prologis (PLD) trades at $127.3, down 1.07% on the day, with a bearish technical signal but strong fundamentals including a 45.79% net income margin and three consecutive quarterly EPS beats. The stock is supported by robust cash flow from operations of $5.01B in 2025 and positive leasing momentum highlighted by management. Recent news emphasizes growth from warehouse and data center demand, though technical indicators show selling pressure with key support at $126.
The outlook is mixed: analyst consensus is bullish with a $155.15 price target (59.52% buy ratings), but rising debt-to-asset ratios and bearish moving averages pose risks. Upside hinges on continued execution in logistics real estate, while macroeconomic sensitivity and valuation premiums require monitoring for sustained shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
